Design, synthesis and evaluation of MCH receptor 1 antagonists—Part II: Optimization of pyridazines toward reduced phospholipidosis and hERG inhibition-Reference-Cited by-同舟云学术

Design, synthesis and evaluation of MCH receptor 1 antagonists—Part II: Optimization of pyridazines toward reduced phospholipidosis and hERG inhibition

Published:2015-08 Issue:16 Volume:25 Page:3270-3274
ISSN:0960-894X
Container-title:Bioorganic & Medicinal Chemistry Letters
language:en
Short-container-title:Bioorganic & Medicinal Chemistry Letters

Author:

Roth Gerald J.,Heckel Armin,Kley Jörg T.,Lehmann Thorsten,Müller Stephan G.,Oost Thorsten,Rudolf Klaus,Arndt Kirsten,Budzinski Ralph,Lenter Martin,Lotz Ralf R.H.,Schindler Marcus,Thomas Leo,Stenkamp Dirk

Publisher

Elsevier BV

Subject

Organic Chemistry,Clinical Biochemistry,Drug Discovery,Pharmaceutical Science,Molecular Biology,Molecular Medicine,Biochemistry

Reference11 articles.

1. Drug therapy of the metabolic syndrome: minimizing the emerging crisis in polypharmacy

2. Recent Updates on the Melanin-Concentrating Hormone (MCH) and Its Receptor System: Lessons from MCH1R Antagonists

3. Recent progress in the discovery of melanin-concentrating hormone 1-receptor antagonists

4. Drug-induced phospholipidosis: issues and future directions

5. MCH-R1 antagonists: what is keeping most research programs away from the clinic?

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pyridazinone-based derivatives as anticancer agents endowed with anti-microbial activity: molecular design, synthesis, and biological investigation;RSC Medicinal Chemistry;2024

2. Discovery of 3,6-disubstituted pyridazines as a novel class of anticancer agents targeting cyclin-dependent kinase 2: synthesis, biological evaluation and in silico insights;Journal of Enzyme Inhibition and Medicinal Chemistry;2020-01-01

3. Synthesis and biological evaluation of 3-amino-, 3-alkoxy- and 3-aryloxy-6-(hetero)arylpyridazines as potent antitumor agents;Bioorganic & Medicinal Chemistry Letters;2019-03

4. New pyridazine-based binuclear nickel(ii), copper(ii) and zinc(ii) complexes as prospective anticancer agents;New Journal of Chemistry;2016

5. Design, synthesis and evaluation of MCH receptor 1 antagonists—Part III: Discovery of pre-clinical development candidate BI 186908;Bioorganic & Medicinal Chemistry Letters;2015-08